ArriVent Posts Wider Loss in Fiscal Q2
ArriVent BioPharma ( NASDAQ:AVBP ) , a clinical-stage oncology company, reported its second quarter 2025 earnings on August 11, 2025. The most important update was a wider net loss than expected--the company posted a GAAP loss per share of $ ( 0.90 ) , compared to analyst expectations of $ ( 0.71 ...
New Strong Sell Stocks for July 21st
CDZI, AVBP and ACCO have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2025.
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - BrightView Hldgs ( NYSE:BV ) , ArriVent BioPharma ( NASDAQ:AVBP )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday. Shares of Centene Corporation CNC fell sharply in today's pre-market trading after the health care company withdrew its guidance for 2025.
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
NEWTOWN SQUARE, Pa., July 01, 2025 ( GLOBE NEWSWIRE ) -- ArriVent BioPharma, Inc. ( "ArriVent" ) ( Nasdaq: AVBP ) , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public ...
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
16.0 months median progression free survival ( mPFS ) with firmonertinib 240 mg by blinded independent central review ( BICR ) in first-line patients ...
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
Virtual webinar on June 23, 2025 at 8:00 am ET Virtual webinar on June 23, 2025 at 8:00 am ET ...
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC - ArriVent BioPharma ( NASDAQ:AVBP )
NEWTOWN SQUARE, Pa., June 20, 2025 ( GLOBE NEWSWIRE ) -- ArriVent BioPharma, Inc. ( Company or ArriVent ) AVBP, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the Company will host a virtual investor event ...
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside - ArriVent BioPharma ( NASDAQ:AVBP )
Firmonertinib targets NSCLC with EGFR mutations, a ~$700 million market opportunity. B. Riley expects 50%-100% upside on Phase 3 success. Pelosi's latest AI pick skyrocketed 169% in just one month. Click here to discover the next stock our government trade tracker is spotlighting-before it takes ...
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Amentum Holdings ( NYSE:AMTM ) , ArriVent BioPharma ( NASDAQ:AVBP )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Kalpit Patel initiated coverage on ArriVent BioPharma, Inc.
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket - Allurion Technologies ( NYSE:ALUR ) , Aclarion ( NASDAQ:ACON )
Shares of Logility Supply Chain Solutions, Inc. LGTY rose sharply in today's pre-market trading after Aptean announced an agreement to acquire Logility in a $14.30-per-share all-cash deal. Logility Supply Chain Solutions shares jumped 23.2% to $13.95 in the pre-market trading session.
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 ( GLOBE NEWSWIRE ) -- ArriVent BioPharma, Inc. ( Company or ArriVent ) ( Nasdaq: AVBP ) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into ...
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - ArriVent BioPharma ( NASDAQ:AVBP )
Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate ( ADC ) in development for gastrointestinal ( GI ) cancers First Investigational New Drug ( IND ) submission planned for 1H 2025 Expands ArriVent's growing pipeline of next-generation ADCs
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose. 46.2% confirmed ORR in CNS Metastases ...
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
NORWOOD, Mass., Aug. 20, 2024 ( GLOBE NEWSWIRE ) -- Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ: CRBP ) ( "Corbus" or the "Company" ) , today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the ...
Wall Street Analysts Think ArriVent BioPharma, Inc. ( AVBP ) Could Surge 27.26%: Read This Before Placing a Bet
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session ...
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab - ArriVent BioPharma ( NASDAQ:AVBP )
Collaboration will leverage Alphamab's antibody drug conjugate ( "ADC" ) research and discovery platform and ArriVent's global development and commercialization expertise Upfront and milestone payments to Alphamab worth up to $615.5 million for potential ADCs
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Collaboration will leverage Alphamab's antibody drug conjugate ( "ADC" ) research and discovery platform and ArriVent's global development and commercialization expertise ...
ProfoundBio Discovers The Joys Of Having A Wealthy Owner - Genmab ( NASDAQ:GMAB ) , ArriVent BioPharma ( NASDAQ:AVBP )
Cancer treatment maker ProfoundBio announced it will be purchased by Denmark's Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months
Caterpillar Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Caterpillar Likely To Report Higher Q4 Earnings. Here Are The Recent Forecast Changes From Wall Street's Most ... - Markets Insider ...
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying - Cleveland-Cliffs ( NYSE:CLF ) , ArriVent BioPharma ( NASDAQ:AVBP )
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
These are the 7 healthcare startups primed to IPO when the market reopens
The 7 Healthcare Startups Primed to IPO When the Market Reopens - Business Insider ...
